Panelists:
Michelle Fraser, PhD
Head of Cell and Gene Therapy
Revvity
Anastasia L. Kaufman, PhD
Senior Scientist, Base editing R&D,
Cell and Gene Therapy
Revvity
Josh Croteau, PhD
Program Manager, Strategic Partnerships & Commercialization
BioLegend (Revvity)
- Time:
Gene editing platforms like CRISPR-Cas9 that rely on nuclease activity introduce effective modifications, however, they arise from double strand DNA breaks (DSBs) introduced by the nuclease that can lead to unwanted genomic alterations and cytotoxicity. In contrast, base editing modifies DNA by chemically changing one base letter into another. This approach is the foundation of the Pin-point™ base editing platform, which introduces genetic modifications with high editing efficiency and specificity without reliance on DSBs making it ideal for engineering effective cell therapies for various diseases.
In this GEN webinar, our expert speakers will describe the Pin-point base editing platform and how it enables the creation of CAR-T therapies and hypoimmunogenic iPSCs in a single intervention by simultaneously introducing multiple gene knockouts and enabling site-specific integration of a transgene. You’ll hear the results of analyzing an edited T cell population using bulk NGS and single cell multi-omics approaches using TotalSeq™ reagents that confirm the safety and efficiency of editing with the Pin-point platform at the DNA, RNA, and protein level.
Key learnings:
- Uncover the fundamentals of the Pin-point base editing platform and how it works
- Discover why base editing has a stronger safety profile than traditional CRISPR-Cas9 gene editing
- Learn how to leverage the Pin-point platform for complex engineering projects
- Discover how TotalSeq reagents can integrate whole transcriptome and highly-multiplexed protein analysis in a single-cell multiomics analysis to deeply interrogate gene-edited cells
A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelists.
Produced with support from:
